Taiflex Scientific Co., Ltd. (TPE:8039)

CTI BioPharma Balance Sheet

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	2,753	2,889	1,965	2,264	3,270	1,794
Short-Term Investments	0.43	200	-	30.74	276.9	79
Trading Asset Securities	67.48	30.68	27.75	26.74	25.59	29.41
Cash & Short-Term Investments	2,821	3,120	1,993	2,322	3,573	1,902
Cash Growth	-1.46%	56.54%	-14.16%	-35.01%	87.84%	-28.72%
Accounts Receivable	3,874	3,784	3,816	3,693	3,963	4,182
Other Receivables	110.67	97.98	52.91	36.87	50.52	54.6
Receivables	3,984	3,882	3,869	3,730	4,014	4,237
Inventory	2,326	1,652	1,410	1,771	1,869	1,282
Prepaid Expenses	110.33	71.13	48.98	42.17	51.91	77.4
Other Current Assets	62.09	50.94	53.75	48.31	49.54	83.04
Total Current Assets	9,303	8,776	7,375	7,913	9,557	7,582
Property, Plant & Equipment	4,916	5,010	4,892	4,287	3,731	3,558
Long-Term Investments	313	446.4	441.81	283.2	413.68	40.98
Goodwill	-	69.78	69.78	69.78	69.78	69.78
Other Intangible Assets	177.72	72.29	81.32	94.27	92.6	54.27
Long-Term Deferred Tax Assets	219.08	135.5	157.05	175.6	195.57	200.96
Other Long-Term Assets	24.09	16.99	14.7	24.14	14.94	26.52
Total Assets	14,953	14,527	13,031	12,848	14,075	11,532
Accounts Payable	1,870	1,374	1,061	752.77	1,280	1,748
Short-Term Debt	405.27	343.78	218.86	255	790	150
Current Portion of Long-Term Debt	49.09	19.5	1,928	69.26	50	25
Current Portion of Leases	18.15	18.76	19.78	21.93	16.35	16.6
Current Income Taxes Payable	321.46	245	216.71	275.03	133.23	276.05
Current Unearned Revenue	1.4	1.16	1.47	0.76	1.85	2.51
Other Current Liabilities	1,477	823.78	657.46	694.47	663.72	588.05
Total Current Liabilities	4,142	2,826	4,103	2,069	2,935	2,806
Long-Term Debt	536.81	570.38	345.52	2,179	2,615	539
Long-Term Leases	204.78	200.92	247.36	259.84	250.69	256.65
Long-Term Deferred Tax Liabilities	112.84	148.01	118.08	108.38	111.83	89.64
Other Long-Term Liabilities	87.62	1.74	16	0.26	0.26	0.26
Total Liabilities	5,084	3,862	4,963	4,795	6,161	3,954
Common Stock	2,567	2,549	2,091	2,091	2,091	2,091
Additional Paid-In Capital	2,336	2,322	1,026	1,141	1,146	1,066
Retained Earnings	5,069	5,584	5,035	4,986	4,764	4,537
Comprehensive Income & Other	-190.32	188.45	-164.69	-310.18	-236	-234.3
Total Common Equity	9,781	10,644	7,987	7,908	7,765	7,460
Minority Interest	87.82	21.5	81.33	144.04	148.1	118.07
Shareholders' Equity	9,869	10,666	8,069	8,052	7,913	7,578
Total Liabilities & Equity	14,953	14,527	13,031	12,848	14,075	11,532
Total Debt	1,214	1,153	2,759	2,785	3,722	987.25
Net Cash (Debt)	1,606	1,967	-766.3	-462.78	-149.35	914.79
Net Cash Growth	106.52%	-	-	-	-	26.00%
Net Cash Per Share	6.13	7.59	-2.91	-1.77	-0.58	4.15
Filing Date Shares Outstanding	251.9	254.91	218.74	218.74	218.74	218.74
Total Common Shares Outstanding	251.9	254.91	218.74	218.74	218.74	218.74
Working Capital	5,161	5,950	3,271	5,844	6,622	4,775
Book Value Per Share	38.83	41.76	36.52	36.15	35.50	34.10
Tangible Book Value	9,603	10,502	7,836	7,744	7,603	7,336
Tangible Book Value Per Share	38.12	41.20	35.82	35.40	34.76	33.54
Land	-	350.33	335.23	327.94	100.84	100.84
Buildings	-	2,374	1,998	1,849	1,720	1,639
Machinery	-	6,002	5,303	4,796	4,439	4,167
Construction In Progress	-	606.55	1,032	678.59	515.43	421.25

Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.